GlassScriptPhysician profile
Nancy Ervin Breslin
NPI 1871733808
$8,927.13
in general payments reported to CMS, 2019-2025
55 companies · $821 in 2025
The $821 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,648 · 2022: $4,739 · 2023: $540 · 2024: $178 · 2025: $821.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,540.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,539.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $733.72 | 2021-2023 | Lumakras |
| Astrazeneca Pharmaceuticals LP | $568.16 | 2021-2025 | Imfinzi |
| Incyte Corporation | $489.16 | 2021-2023 | Jakafi |
| Novartis Pharmaceuticals Corporation | $476.69 | 2021-2023 | Kisqali, Piqray |
| Merck Sharp & Dohme LLC | $461.45 | 2021-2023 | Keytruda, Lynparza |
| Seagen INC. | $453.87 | 2021-2023 | Padcev |
| Daiichi Sankyo INC. | $386.49 | 2021-2025 | Vanflyta |
| Pfizer INC. | $381.41 | 2021-2023 | |
| Janssen Biotech, INC. | $373.32 | 2021-2023 | Erleada |
| Genzyme Corporation | $357.47 | 2021-2025 | |
| Eisai INC. | $338.76 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $325.96 | 2021-2023 | Opdualag |
| Abbvie INC. | $283.61 | 2021-2025 | |
| Gilead Sciences, INC. | $215.37 | 2022-2024 | Trodelvy |
| Kite Pharma, INC. | $205.60 | 2021-2023 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Breslin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.